Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease

Journal of Neurochemistry

Volumn 86, Issue 5, 2003, Pages 1142-1148

  Faucheux, Baptiste A ^a,b   Martin, Marie Elise ^c   Beaumont, Carole ^c   Hauw, Jean Jacques ^b   Agid, Yves ^a   Hirsch, Etienne C ^a  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Iron; Neuromelanin; Parkinson's disease; Redox activity; Substantia nigra

Indexed keywords

FERRIC ION; FERROUS ION; HEME; IRON; LEVODOPA; NEUROMELANIN;

AGED; ARTICLE; AUTOPSY; CELL AGGREGATION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METAL BINDING; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

PARKINSONIA;

EID: 0042433192     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01923.x     Document Type: Article

References (41)

1. Aime S., Bergamasco B., Biglino D., Digilio G., Fasano M., Giamello E. and Lopiano L. (1997) EPR investigations of the iron domain in neuromelanin. Biochem. Biophys. Acta 1361, 49-58.
2. Aisen P., Wessling-Resnick M. and Leibold E. A. (1999) Iron metabolism. Curr. Opin. Chem. Biol. 3, 200-206.
3. Ben-Shachar D., Riederer P. and Youdim M. B. H. (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
4. Castellani R. J., Siedlak S. L., Perry G. and Smith M. A. (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100, 111-114.
5. Connor J. R., Snyder B. S., Arosio P., Loeffier D. A. and LeWitt P. (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65, 717-724.
6. Damier P., Hirsch E. C., Agid Y. and Graybiel A. M. (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122, 1437-1448.
7. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
8. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P. and Marsden D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
9. Double K., Zecca L., Costo P., Mauer M., Greisinger C., Ito S., Ben-Shachar D., Brigmann G., Fariello R. G., Riederer P. and Gerlach M. (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75, 2583-2589.
10. Double K. L., Ben-Shachar D., Youdim M. B. H., Zecca L., Riederer P. and Gerlach M. (2002) Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24, 621-628.
11. Earle K. M. (1968) Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropathol. Exp. Neurol. 27, 1-14.
12. Faucheux B. A., Bonnet A. M., Agid Y. and Hirsch E. C. (1999) Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353, 981-982.
13. Faucheux B. A., Martin M. E., Beaumont C., Hunot S., Hauw J. J., Agid Y. and Hirsch E. C. (2002) Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83, 320-330.
14. Gerlach M., Trautwein A. X., Zecca L., Youdim M. B. H. and Riederer P. (1995) Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65, 923-926.
15. Good P. F., Olanow C. W. and Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res. 593, 343-346.
16. Gorell J. M., Ordidge R. J., Brown G. G., Deniau J. C., Buderer N. M. and Helpern J. A. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45, 1138-1143.
17. Gutteridge J. M. (1992) Iron and oxygen radicals in brain. Ann. Neurol. 32, S16-S21.
18. Harrison P. M. and Arosio P. (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161-203.
19. Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
20. Hoehn M. M. and Yahr M. D. (1967) Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
21. Jellinger K. A. (2002) Recent developments in the pathology of Parkinson's disease. J. Neural Transm. 62, 347-376.
22. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P. and Youdim M. B. H. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. (Park. Dis. Dementia Section) 2, 327-340.
23. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D. and Youdim M. B. H. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59, 1168-1171.
24. Jenner P. and Olanow C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72-S84.
25. Kastner A., Hirsch E. C., Lejeune O., Javoy-Agid F., Rascol O. and Agid Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
26. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J. Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M. F., DiMonte D., Volitaskis I., Ellerby L., Chemy R. A., Bush A. I. and Andersen J. K. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
27. Kienzl E., Puchinger L., Jellinger K., Linert W., Stachelberger H. and Jameson R. F. (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134, 69-78.
28. Kienzl E., Jellinger K., Stachelberger H. and Linert W. (1999) Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? Life Sci. 65, 1973-1976.
29. Lin E., Graziano J. H. and Freyers G. A. (2001) Regulation of the 75-kDa subunit of mitochondrial complex I by iron. J. Biol. Chem. 276, 27685-27692.
30. Mann V. M., Cooper J. M., Daniel S. E., Srai K., Jenner P., Marsden C. D. and Schapira A. H. V. (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36, 876-881.
31. Moos T. (2000) Absence of ferritin protein in substantia nigra pars compacta neurons. A reappraisal to the role of iron in Parkinson disease pathogenesis. Movement Disorders 15, 319A.
32. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer M. and Wolozin B. (2000) The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054.
33. Riederer P., Dirr A., Goetz M., Sofic E., Jellinger K. and Youdim M. B. H. (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 32, S101-S104.
34. Schipper H. M., Vininsky R., Brull R., Small L. and Brawer J. R. (1998) Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp. Neurol. 152, 188-196.
35. Smith M. A., Harris P. L. R., Sayre L. M. and Perry G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866-9868.
36. Smythies J. (1996) On the function of neuromelanin. Proc. Royal Soc. Lond. Series B 263, 487-489.
37. Youdim M. B. H., Ben-Shachar D. and Riederer P. (1993) The possible role of iron in the etiopathology of Parkinson's disease. Movement Disorders 8, 1-12.
38. Zareba M., Bober A., Korytowski W., Zecca L. and Sama T. (1995) The effect of synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta 1138, 6-10.
39. Zecca L., Gallorini M., Schünemann V., Trautwein A. X., Gerlach M., Riederer P., Vezzoni P. and Tampellini D. (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766-1773.
40. Zecca L., Tampellini D., Gatti A., Crippa R., Eisner M., Sulzer D., Ito S., Fariello R. and Gallorini M. (2002a) The neuromelanin of human substantia nigra and its interaction with metals. J. Neural Transm. 109, 663-672.
41. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A. and Tampellini D. (2002b) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510, 216-220.